Clinical impact of brachyury expression in Ewing sarcoma patients

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorABRAHAO-MACHADO, Lucas Faria
dc.contributor.authorPINTO, Filipe
dc.contributor.authorANTUNES, Bruno
dc.contributor.authorVOLC, Sahlua
dc.contributor.authorBOLDRINI, Erica
dc.contributor.authorCAMARGO, Olavo Pires de
dc.contributor.authorREIS, Rui M.
dc.date.accessioned2021-12-16T14:27:42Z
dc.date.available2021-12-16T14:27:42Z
dc.date.issued2021
dc.description.abstractPurpose: The T-box transcription factor brachyury has been demonstrated as a prognostic factor in a variety of cancer types and considered a novel oncotarget in solid tumors. Brachyury acts as a regulator of the epithelialmesenchymal transition (EMT) process, leading to more aggressive behavior and poorer prognosis. However, recent literature evidence suggests a tumor suppressor role in other neoplasms. In the present study, we aimed to study brachyury expression and its prognostic impact in Ewing sarcoma, an aggressive neoplasm of young individuals. Methods: We analyzed the expression of brachyury by immunohistochemistry in a series of 96 Ewing sarcomas in a tissue microarray and investigated the association of the protein expression with the clinical parameters and overall survival. Results: More than half of the cases (51%, n = 49) depicted positive nuclear brachyury expression, while a lack of expression was observed in 49% (n = 47) of cases. Nuclear brachyury staining was significantly associated with non-white ethnicity (p = 0.04) and axial localization (p = 0.025). Importantly, lack of brachyury expression was significantly associated with lower overall survival in multivariate analyses (hazard ratio - HR: 2.227, p = 0.008). Conclusions: Our findings indicate, that brachyury is an independent prognostic biomarker in Ewing sarcoma, which might suggest a tumor suppressor role and which yet to be fully elucidated.eng
dc.description.indexMEDLINEeng
dc.description.sponsorshipBarretos Cancer Hospital
dc.identifier.citationADVANCES IN MEDICAL SCIENCES, v.66, n.2, p.321-325, 2021
dc.identifier.doi10.1016/j.advms.2021.06.002
dc.identifier.eissn1898-4002
dc.identifier.issn1896-1126
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/43916
dc.language.isoeng
dc.publisherELSEVIER URBAN & PARTNER SP Z O Oeng
dc.relation.ispartofAdvances in Medical Sciences
dc.rightsrestrictedAccesseng
dc.rights.holderCopyright ELSEVIER URBAN & PARTNER SP Z O Oeng
dc.subjectBrachyuryeng
dc.subjectEwing sarcomaeng
dc.subjectBiomarkerseng
dc.subjectPrognosiseng
dc.subjectTumor suppressoreng
dc.subject.otherepithelial-mesenchymal transitioneng
dc.subject.othertranscription factoreng
dc.subject.othertumorseng
dc.subject.otherfamilyeng
dc.subject.otherbiomarkereng
dc.subject.otherchordomaeng
dc.subject.othermarkereng
dc.subject.wosMedicine, Research & Experimentaleng
dc.titleClinical impact of brachyury expression in Ewing sarcoma patientseng
dc.typearticleeng
dc.type.categoryoriginal articleeng
dc.type.versionpublishedVersioneng
dspace.entity.typePublication
hcfmusp.affiliation.countryPortugal
hcfmusp.affiliation.countryisopt
hcfmusp.author.externalABRAHAO-MACHADO, Lucas Faria:Barretos Canc Hosp, Dept Pathol & Mol Diag, Barretos, SP, Brazil; Bacchi Lab, R Maj Leonidas Cardoso 739, BR-18602010 Botucatu, SP, Brazil
hcfmusp.author.externalPINTO, Filipe:Univ Minho, Sch Med, Life & Hlth Sci Res Inst ICVS, Braga, Portugal; ICVS 3Bs PT Govt Associate Lab, Braga, Guimaraes, Portugal; Univ Porto, I3S Inst Investigagao & Inovacao Satide, P-4200135 Porto, Portugal
hcfmusp.author.externalANTUNES, Bruno:Barretos Canc Hosp, Dept Orthoped Surg, Barretos, SP, Brazil
hcfmusp.author.externalVOLC, Sahlua:Barretos Canc Hosp, Oncol Dept, Barretos, SP, Brazil
hcfmusp.author.externalBOLDRINI, Erica:Barretos Canc Hosp, Pediat Dept, Barretos, SP, Brazil
hcfmusp.author.externalREIS, Rui M.:Univ Minho, Sch Med, Life & Hlth Sci Res Inst ICVS, Braga, Portugal; ICVS 3Bs PT Govt Associate Lab, Braga, Guimaraes, Portugal; Barretos Canc Hosp, Mol Oncol Res Ctr, Barretos, SP, Brazil
hcfmusp.citation.scopus0
hcfmusp.contributor.author-fmusphcOLAVO PIRES DE CAMARGO
hcfmusp.description.beginpage321
hcfmusp.description.endpage325
hcfmusp.description.issue2
hcfmusp.description.volume66
hcfmusp.origemWOS
hcfmusp.origem.pubmed34273746
hcfmusp.origem.scopus2-s2.0-85109884095
hcfmusp.origem.wosWOS:000709703800014
hcfmusp.publisher.cityWROCLAWeng
hcfmusp.publisher.countryPOLANDeng
hcfmusp.relation.referenceAbrahao-Machado LF, 2018, BIOMARK MED, V12, P35, DOI 10.2217/bmm-2017-0152eng
hcfmusp.relation.referenceBrunetto AL, 2015, PEDIATR BLOOD CANCER, V62, P1747, DOI 10.1002/pbc.25562eng
hcfmusp.relation.referenceCash T, 2016, PEDIATR BLOOD CANCER, V63, P1771, DOI 10.1002/pbc.26096eng
hcfmusp.relation.referenceChaffer CL, 2016, CANCER METAST REV, V35, P645, DOI 10.1007/s10555-016-9648-7eng
hcfmusp.relation.referenceDE Alava E, 2013, EWING SARCOMA WHO CL, P306eng
hcfmusp.relation.referenceFernando RI, 2010, J CLIN INVEST, V120, P533, DOI 10.1172/JCI38379eng
hcfmusp.relation.referenceGaspar N, 2015, J CLIN ONCOL, V33, P3036, DOI 10.1200/JCO.2014.59.5256eng
hcfmusp.relation.referenceHamilton DH, 2017, CELLS TISSUES ORGANS, V203, P128, DOI 10.1159/000446495eng
hcfmusp.relation.referenceHamilton DH, 2013, ONCOTARGET, V4, P1777, DOI 10.18632/oncotarget.1295eng
hcfmusp.relation.referenceHamilton SN, 2017, AM J CLIN ONCOL-CANC, V40, P423, DOI 10.1097/COC.0000000000000176eng
hcfmusp.relation.referenceHaro A, 2013, ANN SURG ONCOL, V20, pS509, DOI 10.1245/s10434-013-2914-9eng
hcfmusp.relation.referenceKim SK, 2016, HUM PATHOL, V55, P91, DOI 10.1016/j.humpath.2016.05.008eng
hcfmusp.relation.referenceMiettinen M, 2015, AM J SURG PATHOL, V39, P1305, DOI 10.1097/PAS.0000000000000462eng
hcfmusp.relation.referencePalena C, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju054eng
hcfmusp.relation.referencePinto F, 2018, ANDROLOGY-US, V6, P597, DOI 10.1111/andr.12495eng
hcfmusp.relation.referencePinto F, 2020, NEUROTHERAPEUTICS, V17, P2015, DOI 10.1007/s13311-020-00911-9eng
hcfmusp.relation.referencePinto F, 2020, J PATHOL, V251, P87, DOI 10.1002/path.5419eng
hcfmusp.relation.referencePinto F, 2016, GASTRIC CANCER, V19, P651, DOI 10.1007/s10120-015-0505-0eng
hcfmusp.relation.referencePinto F, 2014, CLIN CANCER RES, V20, P4949, DOI 10.1158/1078-0432.CCR-14-0421eng
hcfmusp.relation.referenceRobinson H, 2020, TRENDS CANCER, V6, P271, DOI 10.1016/j.trecan.2020.01.014eng
hcfmusp.relation.referenceRodriguez-Galindo C, 2007, CANCER-AM CANCER SOC, V110, P375, DOI 10.1002/cncr.22821eng
hcfmusp.relation.referenceRoselli M, 2012, CLIN CANCER RES, V18, P3868, DOI 10.1158/1078-0432.CCR-11-3211eng
hcfmusp.relation.referenceSannino G, 2017, CANCER RES, V77, P4556, DOI 10.1158/0008-5472.CAN-17-0032eng
hcfmusp.relation.referenceSbaraglia M, 2020, VIRCHOWS ARCH, V476, P109, DOI 10.1007/s00428-019-02720-8eng
hcfmusp.relation.referenceTirabosco R, 2008, AM J SURG PATHOL, V32, P572, DOI 10.1097/PAS.0b013e31815b693aeng
hcfmusp.relation.referenceVujovic S, 2006, J PATHOL, V209, P157, DOI 10.1002/path.1969eng
hcfmusp.relation.referenceWILKINSON DG, 1990, NATURE, V343, P657, DOI 10.1038/343657a0eng
hcfmusp.relation.referenceWold L.E., 2005, AM REGIST PATHOLeng
hcfmusp.scopus.lastupdate2024-05-10
relation.isAuthorOfPublication7aaab6ad-0d2e-4150-9a94-5ef2fe8a6680
relation.isAuthorOfPublication.latestForDiscovery7aaab6ad-0d2e-4150-9a94-5ef2fe8a6680
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
art_ABRAHAO-MACHADO_Clinical_impact_of_brachyury_expression_in_Ewing_sarcoma_2021.PDF
Tamanho:
823.5 KB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - FM/MOT
Artigos e Materiais de Revistas Científicas - LIM/41
Artigos e Materiais de Revistas Científicas - ODS/03